Download a PDF of the deck, "Targeting Aldosterone in HF and CKD" (PDF will download to your computer or open in new window, depending on your browser settings).
References
KDIGO CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314.
Heidenreich et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145(18):e895-e1032.
de Boer IH, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45:3075-3090.
Maruyama et al. Cardiovascular, renal and mortality risk by the KDIGO heatmap in Japan. Clin Kidney J. 2024:17(8):sfae228
Lala A, et al. The interplay between heart failure and chronic kidney disease. Diabetes Obes Metab. 2025;27(7):3568-3582.
Marassi M and Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovasc Diabetol. 2023:22:195.
Wong K, et al. Comparison of demographic factors and cardiovascular risk factor control among U.S. adults with type 2 diabetes by insulin treatment classification. J Diabetes Complications. 2012;26:169-174.
Feng X, et al. CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States. Kidney Med. 2022;4(1):100385.
Burrows NR, et al. Reported Cases of End-Stage Kidney Disease. MMWR Morb Mortal Wkly Rep. 2022;71(11):412-415.
Rangaswami J, et al. Cardiorenal Protection With the Newer Antidiabetic Agents. Circulation. 2020;142(17):e265-e268.
Kushner PR, et al. Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Diseases. Clin Diabetes. 2022; 40(4):401-412.
Alfego D, et al. Chronic Kidney Disease Testing Among At-Risk Adults in the U.S. Remains Low: Real-World Evidence From a National Laboratory Database. Diabetes Care. 2021;44:2025-2032
Shin J, et al. Albuminuria testing in hypertension and diabetes: An individual-Participant data meta-analysis in a global consortium. Hypertension. 2021;78:1042-1052.
Kosyakovsky LB, et al. Uncovering Unrecognized Heart Failure With Preserved Ejection Fraction Among Individuals With Obesity and Dyspnea. Circ Heart Fail. 2024; 7(5):e011366.
Shubrook JH, et al. Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations. Postgrad Med. 2022;134(4):376-387.
Kushner PR, et al. Role of Primary Care Clinicians in the Management of Patients With Type 2 Diabetes and Cardiorenal Disease. Clin Diabetes. 2022; 40(4):401-412.
Otsuka H, et al. The Effect of Aldosterone on Cardiorenal and Metabolic Systems. Int J Mol Sci. 2023;24(6):5370.
Kobayashi M, et al. Aldosterone-targeted therapies: early implementation in resistant hypertension and chronic kidney disease. Eur Heart J. 2025;46(27):2618-2642.
Judge PK, et al. The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial. Nephrol Dial Transplant. 2025; 40(6):1175-1186.
Alfarano M, et al. Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice. JACC Adv. 2025; 4(6 Pt 1):101762.
Bakris GL, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229.
Pitt B, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263.
Solomon SD, et al. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2024;391(16):1475-1485.
Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380:2295-2306.
Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383:1436-1446.
The EMPA-KIDNEY Collaborative Group. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med.
2023;388:117-127.
Aklilu AM, et al. Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitor Use in Acute Heart Failure Hospitalizations Complicated by AKI. Kidney360. 2023. doi:10.34067/KID.0000000000000250.
McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381:1995-2008.
Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387:1089-1098.
Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383:1413-1424.
Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385:1451-1461.
Bhatt DL, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384:117-128.
Invokana [Package Insert]. Updated December 2024. Accessed March 17, 2025.
Farxiga [Package Insert]. Updated October 2024. Accessed March 17, 2025.
Jardiance [Package Insert]. Updated September 2023. Accessed March 17, 2025.
Inpefa [Package Insert]. Updated January 2024. Accessed March 17, 2025.
Colhoun HM, et al. Deciphering the Effects of Semaglutide Across the Glycemic Spectrum. Nat Med. May 25, 2024, online ahead of print. doi:10.1038/s41591-024-03015-5.
Heerspink HJL, et al. Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trials. Diabetes Obes Metab. 2023. doi:10.1111/dom.15232.
Agarwal R, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-543.
Nee R, et al. Overcoming barriers to implementing new guideline-directed therapies for chronic kidney disease. Nephrol Dial Transplant. 2023;38(3):532-541.